Retina Consultants of Southern Colorado, P.C.
2770 North Union Blvd., Suite 140
Colorado Springs, CO 80909
719-473-9595

## CURRENT POSITION

2000-Present Retina Consultants of Southern Colorado, P.C.
Colorado Springs, CO

## EMPLOYMENT HISTORY

1985-1989 Lecturer in Percussion
DePaul University
Chicago, IL

1989-1990 Coordinator of the Eye Trauma Service
Department of Ophthalmology, University of Illinois at Chicago
Chicago, IL

1990-1994 Research Assistant in Ocular Trauma and Retinal Metabolism
Department of Ophthalmology, University of Illinois at Chicago
Chicago, IL

## EDUCATION

1977-1981 Bachelor of Music
University of Iowa
Iowa City, IA

1983-1985 Master of Music
DePaul University
Chicago, IL

## POSTGRADUATE TRAINING

1990-1994 Medical School
University of Illinois at Chicago College of Medicine
Alpha Omega Alpha
Chicago, IL

1994-1995 Transitional Internship
Illinois Masonic Medical Center
Chicago, IL

1995-1998 Ophthalmology Residency
Eye and Ear Infirmary, University of Illinois at Chicago
Chicago, IL

1998-2000 Vitreoretinal Surgery Fellowship
Associated Retinal Consultants, William Beaumont Hospital
Grosse Pointe, MI

## HOSPITAL PRIVILEGES

| | |
|---|---|
| 1987-Present | Penrose-St. Francis Medical Center<br>Colorado Springs, CO |
| 1987-Present | Memorial Hospital<br>Colorado Springs, CO |
| 2013 – Present | Pinnacle Surgery Center<br>Colorado Springs, CO |

## BOARD CERTIFICATION

2000 Ophthalmology

## PROFESSIONAL SOCIETIES

Pi Kappa Lambda
Alpha Omega Alpha
American Academy of Ophthalmology
American Society of Retinal Specialists
Association for Research in Vision and Ophthalmology
Colorado Medical Society
El Paso County Medical Society
Aspen Retinal Detachment Society
Wilderness Medical Society

## CLINICAL RESEARCH

Principal Investigator:

Alcon C-12-1074
: Advanced AMD Phase 1 trial-A Multicenter, Open-Label, Single Ascending Dose Study to Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects with Advanced Age-Related Macular Degeneration

Alcon LHA510-2201
: A Randomized, Double-Masked, Vehicle-Controlled Proof-of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients with Wet Age-Related Macular Degeneration

Genentech/Roche GX29185 (Spectri)
: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Genentech/Roche GX30191 (Omaspect)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration who have Completed a Roche-Sponsored Study

Novartis CLFG316A2203
A Multicenter, Randomized, Sham-Control, Proof-of-Concept Study of Intravitreal LFG316 in Patients with Geographic Atrophy Associated with Age-Related Macular Degeneration

Opthea OPT-302-1002
A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)

Opthea OPT-302-1003
Phase 1b/2a Study of OPT-302 In Combination with Aflibercept For Persistent Central-involved Diabetic Macular Edema

Regeneron VGFTe-OD-1411 (Panorama)
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy

Regeneron VGFT-OD-1009 (Vista)
A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGT-Trap-Eye in Patients with Diabetic Macular Edema

Sub-investigator:

Adverum ADVM-022-02 (NAb)
Blood Specimen Collection Study for the ameasurement of Adeno-Associated Virus (AAV) Neutralizing Antibodies in Subjects with Neovascular (Wet) Age-Related Macular Degeneration

Adverum ADVM-022-01 (Optic)
An Open Label Phase I Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

Aerpio AKB-9778-CI-5001 (Time-2B)
Phase 2 Double-masked, Placebo-controlled Study To Assess The Safety And Efficacy Of Subcutaneously Administered AKB-9778 15mg Once Daily Or 15mg Twice Daily For 12 Months In Patients With Moderate To Severe Non-Proliferative Diabetic Retinopathy

Alcon C-12-006ESBA1008 (Osprey)
A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 versus EYLEA in Subjects with Exudative Age-Related Macular Degeneration

Alcon C-10-083ESBA1008 (See)
Safety and Efficacy Study of ESBA1008 versus Lucentis for the Treatment of Exudative Age-Related Macular Degeneration

Alcon/Novartis RTH258-C001 (Hawk)
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration

Allegro DME-202B (Del Mar)
A Phase 2 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate (ALG-1001) as Compared to AVASTIN in the Treatment of Diabetic Macular Edema

Allergan 206207-024 (Ozurdex)
A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema/Phase

Allergan 190342-038 (Beacon)
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

Allergan 150998-004 (Palm)
Evaluation of Abicipar Pegol (AGN-150998) in Patients with Decreased Vision Due to Diabetic Macular Edema

Ampio AP-05-002
A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral OPTINA in Adult Patients

Chengdu Kanghong KHB-1802 (Panda)
A Multicenter, Double-masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration

Fast Track/60° Pharmaceuticals 60PH04 (Tafenoquine)
Multisite, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine

Genentech FVF4579g (Harbor)
A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Genentech FVF4967g (Shore)
A Multi-Center Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion

Genentech/Roche GX28228 (Ladder)
A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Genentech/Roche GR39821 (HtrA1)
A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation, and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7171009 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Genentech/Roche GR40398 (Rhine)
A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema

Genentech/Roche GR40306 (Tenaya)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab In Patients With Neovascular Age-Related Macular Degeneration

Genentech/Roche BP29647 (Avenue)
A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Genentech/Roche BP30099 (Boulevard)
A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema

Genentech/Roche CR39521 (Stairway)
Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

MacTel NHOR Registry
A Natural History Observation and Registry Study of Macular Telangiectasia Type 2

Neurotech pharmaceuticals NTMT-03-A (Renexus) Macular Telangiectasia
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia type 2

Novartis CRTH258B2301 (Kestrel)
A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema

Novartis CRTH258AUS04 (Merlin)
A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg q4 weeks compared to aflibercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid

Novartis CRTH258A2301E1 (Hawk Extension)
A 24 week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study

Novartis CRTH258C2301 (Raptor)
An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion (RAPTOR)

Novartis CRTH258C2302 (Raven)
An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)

Ophthotech OPH1002A (Eclipse)
A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration

Ophthotech OPH1004 (Solaris)
A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti-PDGF-B Pegylated Aptamer) Administered in combination with Either Avastin or Eylea Compared to Avastin or Eylea Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration

Pan Optica PAN-01-101
: A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD)

pSIVIDA PSV-FAI-001
: A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye

pSIVIDA PSV-FAI-006
: A Controlled, Multi-Center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects with Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Quark QRK207
: A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute NonArteritic Anterior Ischemic Optic Neuropathy (NAION)

Regeneron R2176-3-AMD-1417 (Capella)
: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration

Regeneron VGFT-OD-0605 (View 1)
: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration

Regeneron VGFTe-AMD-1124, Phase IV (Review)
: An Open-Label Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration

Regeneron R2176-3-AMD-1303
: An Open-Label, Dose Escalation Study of the Safety and Tolerability of Intravitreal REGN2176-3 in Patients with Neovascular Age Related Macular Degeneration/Phase 1

Regeneron VGFTe-RVO-1027 (Vibrant)
: A Double-Masked, Randomized, Active-Control Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Regeneron R910-3-DME-1518 (Ruby)

A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema

Samsung SB11-G31-AMD

A Phase III Randomized, Double-masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar and Lucentis in Subjects with Neovascular Age-related Macular Degeneration

Tyrogenex X82-OPH-201

A Randomized, Double-masked, Placebo-controlled, Dose-finding, Non-inferiority Study of X-82 plus prn IVT Anti-VEGF Compared to prn IVT Anti-VEGF Monotherapy in Neovascular AMD/Phase 2b

## PUBLICATIONS

Intraocular fibrinolysis using plasmin in a rabbit model. Williams JG, Hartzer MK, Trese MT, Williams GA. In press.

Autologous Plasmin Enzyme in the surgical management of diabetic retinopathy. Williams JG, Trese MT, Williams GA, Hartzer MK. Ophthalmology. October 2001;108:1902-1905.

A macular lesion simulating an aberrant cryotherapy lesion in retinopathy of prematurity. Williams JG, Trese MT. Archives of Ophthalmology. March 2000;118:438-439.

Ocular toxicity and effects on the growth of retinoblastoma cells of NF-145, a suramin analogue. Williams JG, Hartzer MK, Dailey W, Hassan TS, Kouba B, Gagliardi ART. Investigative Ophthalmology. March 1999;40(suppl):S162.

Ocular toxicity and effects on the growth of retinal pigment epithelial cells by agaricus bisporus lectin. Thomas V, Hartzer MK, Williams JG, Garretson BR, Cheng M. Investigative Ophthalmology. March 1999;40(suppl):S702.

Ocular manifestations of Whipple's Disease. Williams JG, Edward DP, Tessler HH, Persing DH, Mitchell PS, Goldstein DA. Archives of Ophthalmology. September 1998;116:1232-1234.

The outcome of photocoagulation for diabetic macular edema in patients with poor initial visual acuity. Williams JG, Friedlander SM, Shapiro MJ, Resnick KI, Gieser JP, Blair NP. Investigative Ophthalmology. March 1997;38(suppl):S766.

Family history of inflammatory bowel disease in uveitis patients without bowel disease. Phillips BJ, Williams JG, Goldstein DA, Tessler HH. Investigative Ophthalmology. March 1997;38(suppl):S524.

Loss of accommodative amplitude in AIDS patients. Wu P, Williams JG, Phillips BJ, Khanna A, Friedlander SM, Goldstein DA. Investigative Ophthalmology. March 1997;38(suppl):S1101.

An automated information management system for prevention of missed examinations in ROP. Gieser JP, Shapiro MJ, Williams JG. Investigative Ophthalmology. March 1994;35(suppl):S1527.

Patterns in the distribution of ocular trauma at the University of Illinois at Chicago. Williams JG, Shapiro MJ, Moore MA, Resnick KI. Investigative Ophthalmology. March 1992;33(suppl)783.

The relationship between climatological phenomena and ocular trauma. Williams JG, Viana MA, Shapiro MJ. Investigative Ophthalmology. March 1992;33(suppl):783.

Suppression of ischemic retinal injury by verapamil. Tran HN, Blair NP, Glaser DA, Williams JG. Investigative Ophthalmology. March 1992;33(suppl):917.

Chega de saudade: transcription and analysis. Williams JG. Percussive Notes. 1985;22:65-68.

**PRESENTATIONS**

Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Williams JG, Trese MT, Williams GA, Hartzer MK. American Academy of Ophthalmology, October 2000.

Intraocular fibrinolysis using plasmin in a rabbit model. Williams JG, Hartzer MK, Trese MT, Williams GA. ARVO Meeting, May 2000.

Ocular toxicity and effects on the growth of retinoblastoma cells of NF-145. A suramin analogue. Williams JG, Hartzer MK, Dailey W, Hassan TS, Kouba B. ARVO Meeting, May 1999.

Ocular toxicity and effects on the growth of retinal pigment epithelial cells by agaricus bisporus lectin. Thomas V, Hartzer MK, Williams JG, Garretson BR, Cheng M. ARVO Meeting, May 1999.

Outcome of photocoagulation for diabetic macular edema in patients with poor initial visual acuity. Williams JG, Friedlander SM, Shapiro MJ, Resnick KI, Gieser JP, Blair NP. ARVO Meeting, May1997.

Loss of accommodative amplitude in AIDS patients. Wu P, Williams JG, Phillips BJ, Khanna A, Friedlander SM, Goldstein DA. ARVO Meeting, May 1997.

Family history of inflammatory bowel disease in uveitis patients without bowel disease. Phillips BJ, Williams JG, Goldstein DA, Tessler HH. ARVO Meeting, May1997.

An automated information management system for prevention of missed ROP examinations. Gieser JP, Shapiro MJ, Williams JG. ARVO Meeting, May 1994.

Preoperative predictors of ruptured globes. Werner M, Dana M, Williams JG, Viana MA, Shapiro MJ. Second International Symposium of Ocular Trauma. Geneva, Switzerland. April 1992.

The relationship between climatological phenomena and ocular trauma. Williams JG, Viana MA, Shapiro MJ. Second International Symposium of Ocular Trauma. Geneva, Switzerland. April 1992.

Patterns in the distribution of ocular trauma at the University of Illinois at Chicago. Williams JG, Shapiro MJ, Moore MA, Resnick KI. Second International Symposium of Ocular Trauma. Geneva, Switzerland. April 1992.

Suppression of ischemic retinal injury by verapamil. Tran HN, Blair NP, Glaser DA, Williams JG. ARVO Meeting, March 1992.

The relationship between climatological phenomena and ocular trauma. Williams JG, Viana MA, Shapiro MJ. ARVO Meeting, March 1992.

Patterns in the distribution of ocular trauma at the University of Illinois at Chicago. Williams JG, Shapiro MJ, Moore MA, Resnick KI. ARVO Meeting, March 1992.

Epidemiology and prognosis of ocular trauma – a comparison of results between the National Eye Trauma System and the Eye Injury Registry of Alabama. Feist R, Williams JG, Robin J, Morris R, Witherspoon C. Southern Medical Association. Washington D.C., October 1989.